Prognostic impact of the cancer Stem cell-related marker NANOG in ovarian serous carcinoma

Maria Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Jae-Hoon Kim, YoungTae Kim

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Objective: The objective of this study was to evaluate the prognostic significance of NANOG expression in ovarian serous carcinoma. Methods: The expression of NANOG was evaluated in 6 ovarian carcinoma cell lines, paclitaxel-resistant SKOV3 cells, and SKOV3 spheroid cells with semiquantitative reverse transcription-polymerase chain reaction and Western blotting. NANOG expression was also measured immunohistochemically in a tissue microarray containing ovarian tissues from 74 patients with ovarian serous carcinoma and 24 with ovarian serous cystadenoma. Each sample was scored based on signal intensity and proportion, and a score greater than 4 was considered "positive." Results: NANOG mRNA expression was variable in different ovarian cancer cell lines. The mRNA level of NANOG was increased in the paclitaxel-resistant SKOV3 cells and SKOV3 spheroid cells compared with that in the SKOV3 cells. NANOG expression was positive in 21.6% of 74 ovarian serous carcinoma tissues, but none of the ovarian serous cystadenoma tissues were positive. Positive NANOG expression was associated with residual tumor size after surgery (P = 0.032). The overall survival of the patients with positive NANOG expression was poorer than that of the patients with negative NANOG expression (P = 0.020). In patients with stage I and II disease, positive NANOG expression was independently associated with shorter overall survival compared with negative NANOG expression (40 vs 120 months, respectively; P = 0.031). Conclusions: Positive NANOG expression is associated with poor prognosis of ovarian serous carcinoma. NANOG has potential as a predictor of survival for patients with ovarian carcinomas and may be involved in the mechanism of chemoresistance.

Original languageEnglish
Pages (from-to)1489-1496
Number of pages8
JournalInternational Journal of Gynecological Cancer
Volume22
Issue number9
DOIs
Publication statusPublished - 2012 Nov 1

Fingerprint

Neoplastic Stem Cells
Carcinoma
Serous Cystadenoma
Paclitaxel
Survival
Cell Line
Messenger RNA
Residual Neoplasm
Ovarian Neoplasms
Reverse Transcription
Western Blotting
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Oncology
  • Obstetrics and Gynaecology

Cite this

@article{730f58eeae4445d493734701e2096151,
title = "Prognostic impact of the cancer Stem cell-related marker NANOG in ovarian serous carcinoma",
abstract = "Objective: The objective of this study was to evaluate the prognostic significance of NANOG expression in ovarian serous carcinoma. Methods: The expression of NANOG was evaluated in 6 ovarian carcinoma cell lines, paclitaxel-resistant SKOV3 cells, and SKOV3 spheroid cells with semiquantitative reverse transcription-polymerase chain reaction and Western blotting. NANOG expression was also measured immunohistochemically in a tissue microarray containing ovarian tissues from 74 patients with ovarian serous carcinoma and 24 with ovarian serous cystadenoma. Each sample was scored based on signal intensity and proportion, and a score greater than 4 was considered {"}positive.{"} Results: NANOG mRNA expression was variable in different ovarian cancer cell lines. The mRNA level of NANOG was increased in the paclitaxel-resistant SKOV3 cells and SKOV3 spheroid cells compared with that in the SKOV3 cells. NANOG expression was positive in 21.6{\%} of 74 ovarian serous carcinoma tissues, but none of the ovarian serous cystadenoma tissues were positive. Positive NANOG expression was associated with residual tumor size after surgery (P = 0.032). The overall survival of the patients with positive NANOG expression was poorer than that of the patients with negative NANOG expression (P = 0.020). In patients with stage I and II disease, positive NANOG expression was independently associated with shorter overall survival compared with negative NANOG expression (40 vs 120 months, respectively; P = 0.031). Conclusions: Positive NANOG expression is associated with poor prognosis of ovarian serous carcinoma. NANOG has potential as a predictor of survival for patients with ovarian carcinomas and may be involved in the mechanism of chemoresistance.",
author = "Maria Lee and Nam, {Eun Ji} and Kim, {Sang Wun} and Sunghoon Kim and Jae-Hoon Kim and YoungTae Kim",
year = "2012",
month = "11",
day = "1",
doi = "10.1097/IGJ.0b013e3182738307",
language = "English",
volume = "22",
pages = "1489--1496",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

Prognostic impact of the cancer Stem cell-related marker NANOG in ovarian serous carcinoma. / Lee, Maria; Nam, Eun Ji; Kim, Sang Wun; Kim, Sunghoon; Kim, Jae-Hoon; Kim, YoungTae.

In: International Journal of Gynecological Cancer, Vol. 22, No. 9, 01.11.2012, p. 1489-1496.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prognostic impact of the cancer Stem cell-related marker NANOG in ovarian serous carcinoma

AU - Lee, Maria

AU - Nam, Eun Ji

AU - Kim, Sang Wun

AU - Kim, Sunghoon

AU - Kim, Jae-Hoon

AU - Kim, YoungTae

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Objective: The objective of this study was to evaluate the prognostic significance of NANOG expression in ovarian serous carcinoma. Methods: The expression of NANOG was evaluated in 6 ovarian carcinoma cell lines, paclitaxel-resistant SKOV3 cells, and SKOV3 spheroid cells with semiquantitative reverse transcription-polymerase chain reaction and Western blotting. NANOG expression was also measured immunohistochemically in a tissue microarray containing ovarian tissues from 74 patients with ovarian serous carcinoma and 24 with ovarian serous cystadenoma. Each sample was scored based on signal intensity and proportion, and a score greater than 4 was considered "positive." Results: NANOG mRNA expression was variable in different ovarian cancer cell lines. The mRNA level of NANOG was increased in the paclitaxel-resistant SKOV3 cells and SKOV3 spheroid cells compared with that in the SKOV3 cells. NANOG expression was positive in 21.6% of 74 ovarian serous carcinoma tissues, but none of the ovarian serous cystadenoma tissues were positive. Positive NANOG expression was associated with residual tumor size after surgery (P = 0.032). The overall survival of the patients with positive NANOG expression was poorer than that of the patients with negative NANOG expression (P = 0.020). In patients with stage I and II disease, positive NANOG expression was independently associated with shorter overall survival compared with negative NANOG expression (40 vs 120 months, respectively; P = 0.031). Conclusions: Positive NANOG expression is associated with poor prognosis of ovarian serous carcinoma. NANOG has potential as a predictor of survival for patients with ovarian carcinomas and may be involved in the mechanism of chemoresistance.

AB - Objective: The objective of this study was to evaluate the prognostic significance of NANOG expression in ovarian serous carcinoma. Methods: The expression of NANOG was evaluated in 6 ovarian carcinoma cell lines, paclitaxel-resistant SKOV3 cells, and SKOV3 spheroid cells with semiquantitative reverse transcription-polymerase chain reaction and Western blotting. NANOG expression was also measured immunohistochemically in a tissue microarray containing ovarian tissues from 74 patients with ovarian serous carcinoma and 24 with ovarian serous cystadenoma. Each sample was scored based on signal intensity and proportion, and a score greater than 4 was considered "positive." Results: NANOG mRNA expression was variable in different ovarian cancer cell lines. The mRNA level of NANOG was increased in the paclitaxel-resistant SKOV3 cells and SKOV3 spheroid cells compared with that in the SKOV3 cells. NANOG expression was positive in 21.6% of 74 ovarian serous carcinoma tissues, but none of the ovarian serous cystadenoma tissues were positive. Positive NANOG expression was associated with residual tumor size after surgery (P = 0.032). The overall survival of the patients with positive NANOG expression was poorer than that of the patients with negative NANOG expression (P = 0.020). In patients with stage I and II disease, positive NANOG expression was independently associated with shorter overall survival compared with negative NANOG expression (40 vs 120 months, respectively; P = 0.031). Conclusions: Positive NANOG expression is associated with poor prognosis of ovarian serous carcinoma. NANOG has potential as a predictor of survival for patients with ovarian carcinomas and may be involved in the mechanism of chemoresistance.

UR - http://www.scopus.com/inward/record.url?scp=84872325993&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872325993&partnerID=8YFLogxK

U2 - 10.1097/IGJ.0b013e3182738307

DO - 10.1097/IGJ.0b013e3182738307

M3 - Article

VL - 22

SP - 1489

EP - 1496

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 9

ER -